Online inquiry

IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5673MR)

This product GTTS-WQ5673MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GPNMB gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005340.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10457
UniProt ID Q14956
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5673MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2472MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ9078MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ4853MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ5426MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ4376MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ8459MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ2334MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ1765MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW